Skip to main content
. 2023 Feb 7;380:e071058. doi: 10.1136/bmj-2022-071058

Fig 4.

Fig 4

Example of an investigation of the baseline hazard function within each trial of an individual participant data meta-analysis.98 Figure shows the hazard of developing recurrent venous thromboembolism in each trial as a function of the number of years from cessation of treatment after a first unprovoked venous thromboembolism event. All trials had a similar peak in hazard at just under one year from cessation of treatment; however, this peak had varying magnitudes across the seven trials. Figure adapted from Ensor J, Riley RD, Jowett S, et al. Prediction of risk of recurrence of venous thromboembolism following treatment for a first unprovoked venous thromboembolism: systematic review, prognostic model and clinical decision rule, and economic evaluation. Health Technol Assess 2016;20:i-xxxiii, 1-190